MLYS (Mineralys Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is Mineralys Therapeutics Days Payable?

Mineralys Therapeutics MLYS +1.27% 35 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 707 Biotechnology companies, Mineralys Therapeutics ranks worse than 141442.57% on this metric.

Mineralys Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $1.57 Mil. Mineralys Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Mineralys Therapeutics's Days Payable or its related term are showing as below:

MLYS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Mineralys Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Mineralys Therapeutics Days Payable Related Terms

Mineralys Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Days Payable Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Mineralys Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial														0.00	0.00	0.00	0.00	0.00

MLYS vs IDYA, DFTX, TARS: Days Payable Comparison

For the Biotechnology subindustry, Mineralys Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Days Payable falls into.

Save Embed

35GF Score

Mineralys Therapeutics Inc MLYS

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Mineralys Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Mineralys Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.479	+	2.017)	/	2 )	/	0	*	365
=	1.248					/	0	*	365
=	N/A

Mineralys Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (2.017	+	1.116)	/	2 )	/	0	*	365 / 4
=	1.5665					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Mineralys Therapeutics (MLYS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.

Is Mineralys Therapeutics' Days Payable too high?

Mineralys Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Mineralys Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Mineralys Therapeutics' Days Payable compare to IDYA and DFTX?

According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Mineralys Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mineralys Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mineralys Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Mineralys Therapeutics stock overvalued right now?

Mineralys Therapeutics (MLYS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Mineralys Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IDYA DFTX TARS VERA IRON ARQT IMNM CLDX ALMS SLNO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website https://mineralystx.com

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

35GF Score

Get the complete analysis for MLYS

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.68

Price

View MLYS Analysis

See Days Payable data for all stocks →